HIV-1 RNA quantification in CRF02-AG HIV-1 infection: Too easy to make mistakes

New Microbiologica

Volumn 39, Issue 2, 2016, Pages 150-152

  Tatarelli, Paola ^a   Taramasso, Lucia ^a   Di Biagio, Antonio ^a   Sticchi, Laura ^a,b   Nigro, Nicola ^a   Barresi, Renata ^a   Viscoli, Claudio ^a   Bruzzone, Bianca ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Acute HIV 1 infection; CRF02 AG; Genotyping test; HIV; HIV 1 non B subtypes; Recombinant HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADULT; CASE REPORT; CLASSIFICATION; GENETIC REASSORTMENT; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NUCLEIC ACID AMPLIFICATION; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; MALE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; REASSORTANT VIRUSES; RNA, VIRAL; VIRAL LOAD;

EID: 84971426112     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bourlet T., Signori-Schmuck A., Roche L., Icard V., Saoudin H., Trabaud M., et al. (2011). HIV-1 load comparison using four commercial real-time assays. J Clin Microbiol. 49, 292-297.
2. Bruzzone B., Bisio F., Caligiuri P., Mboungou F.A., Nigro N., Sticchi L., et al. (2014). Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo. J Virol Methods. 203, 102-106.
3. Church D., Gregson D., Lloyd T., Klein M., Beckthold B., Laupland K., Gill M.J. (2011). Comparison of the Real Time HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J Clin Microbiol. 49, 118-124.
4. Department of Health and Human Services (DHHS). (2014). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1-239. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (last access June April 2015).
5. European AIDS Clinical Society (EACS). (2014). European Guidelines for treatment of HIV-infected adults in Europe, Version 7.02. Available at http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html (last access June 2015).
6. Gomes P., Carvalho A.P., Diogo I., Gonçalves F., Costa I., Cabanas J., Camacho R.J. (2013). Comparison of the Nucli SENS Easy Q HIV-1 v2.0 with Abbott m2000rt Real Time HIV-1 assay for plasma RNA quantitation in different HIV-1 subtypes. J Virol Methods. 193, 18-22.
7. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. (2011). WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS. 25, 679-689.
8. Henderson G.J., Lee S.K., Irlbeck D.M., Harris J., Kline M., Pollom E., et al. (2012). Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity. Antimicrob Agents Chemother. 56, 623-633.
9. Holguín A., López M., Molinero M., Soriano V. (2008). Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol. 46, 2918-2923.
10. Lai A., Riva C., Marconi A., Balestrieri M., Razzolini F., Meini G., et al. (2010). Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. HIV Med. 11, 593-602.
11. Luft L.M., Gill M.J., Church D.L. (2011). HIV-1 viral diversity and its implications for viral load testing: review of current platforms. Int. J Infect Dis. 15, 661-670.
12. Mellors J.W., Rinaldo C.R. Jr, Gupta P., White R.M., Todd J.A., Kingsley L.A. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 24; 272, 1167-1170. Erratum in: Science. 1997; 275, 14.
13. Ndiaye O., Diop-Ndiaye H., Ouedraogo A.S., Fall-Malick F.Z., Sow-Sall A., Thiam M., et al.; Study Group. (2015). Comparison of four commercial viral load techniques in an area of non-B HIV-1 subtypes circulation. J Virol Methods. 222, 122-131.
14. Peeters M., Aghokeng, A.F., Delaporte, E. (2010). Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin. Microbiol. Infect. 16, 1525-1531.
15. Rhee S.Y., Taylor J., Fessel W.J., Kaufman D., Towner W., Troia P., et al. (2010). HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 54, 4253-4261.
16. Santoro M.M., Alteri C., Ronga L., Flandre P., Fabeni L., Mercurio F., et al. (2012) Comparative analysis of drug resistance among B and the most prevalent non-B HIV Type 1 subtypes (C, F, and CRF02 AG) in Italy. AIDS Research and Human Retroviruses. 10, 1285-1293.
17. Santoro M.M., Perno C.F. (2013). HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol. 17, 4813-4814.
18. Siemieniuk R.A., Beckthold B., Gill M.J. (2013). Increasing HIV subtype diversity and its clinical implications in a sentinel North American population. Can J Infect Dis Med Microbiol. 24, 69-73.
19. Taylor B.S., Sobieszczyk M.E., McCutchan F.E., Hammer S.M. (2008). The Challenge of HIV-1 Subtype Diversity. N Engl J Med. 358, 1590-1602.
20. Troppan K.T., Stelzl E., Violan D., Winkler M., Kessler H.H. (2009). Evaluation of the new VERSANT HIV-1 RNA 1.0 Assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNA. J Clin Virol. 46, 69-74.